BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
Sun Min LimToshio FujinoChulwon KimGwanghee LeeYong-Hee LeeDong Wan KimJin Seok AhnTetsuya MitsudomiTaiguang JinSang-Yoon LeePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
BBT-176 is a fourth-generation EGFR inhibitor showing promising preclinical activity against NSCLC resistant to current EGFR TKIs.